Clinical Trial Update: Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis [NA]

View source ↗

Summary

The clinical trial evaluating tacrolimus for idiopathic focal segmental glomerulosclerosis has been withdrawn. Sponsor: Nanjing University School of Medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Nanjing University School of Medicine | Conditions: Focal Glomerulosclerosis | NA | Status: WITHDRAWN